Fig. 3From: Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysisRisk of bias summary: reviewers’ judgments of each risk of bias item for each eligible studyBack to article page